Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Anixa Biosciences, Inc.
Anixa Biosciences, Inc. News
Dec 15, 2025 - prnewswire.com
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Dec 12, 2025 - feeds.benzinga.com
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why
Dec 11, 2025 - prnewswire.com
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Dec 10, 2025 - prnewswire.com
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences, Inc. Quantitative Score
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Anixa Biosciences, Inc. Financials
Table Compare
Compare ANIX metrics with: | |||
|---|---|---|---|
Earnings & Growth | ANIX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ANIX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ANIX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ANIX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Anixa Biosciences, Inc. Income
Anixa Biosciences, Inc. Balance Sheet
Anixa Biosciences, Inc. Cash Flow
Anixa Biosciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Anixa Biosciences, Inc. Executives
| Name | Role |
|---|---|
| Amit Kumar | Chief Executive Officer, Chairman & Co-Chair of CBAB |
| Michael J. Catelani | President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary |
| Pamela D. Garzone | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Amit Kumar | Chief Executive Officer, Chairman & Co-Chair of CBAB | 1964 | 1.38M | |
| Michael J. Catelani | President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary | Male | 1967 | 713.5K |
| Pamela D. Garzone | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1955 | -- |
Anixa Biosciences, Inc. Insider Trades
| Date | 15 Dec |
| Name | Titterton Lewis H jr |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 16000 |
| Date | 15 Dec |
| Name | Titterton Lewis H jr |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 16000 |
| Date | 30 Oct |
| Name | KUMAR AMIT |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 200000 |
| Date | 30 Oct |
| Name | KUMAR AMIT |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 169439 |
| Date | 30 Oct |
| Name | KUMAR AMIT |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 200000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Dec | Titterton Lewis H jr | Director | Acquired | M-Exempt | 16000 |
| 15 Dec | Titterton Lewis H jr | Director | Disposed | M-Exempt | 16000 |
| 30 Oct | KUMAR AMIT | Chief Executive Officer | Acquired | M-Exempt | 200000 |
| 30 Oct | KUMAR AMIT | Chief Executive Officer | Disposed | F-InKind | 169439 |
| 30 Oct | KUMAR AMIT | Chief Executive Officer | Disposed | M-Exempt | 200000 |